Goldman Sachs initiated coverage of Neurocrine (NBIX) with a Buy rating and $182 price target implying 36% upside potential. The firm says Neurocrine has an attractive growth profile relative to its mid-cap peers, given the ongoing Crenessity launch. The company offers significant upside on positive clinical development over the next several years, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted Valuation
- Neurocrine price target raised to $174 from $152 at UBS
- Neurocrine initiates Phase 1 study of NBIP-01435
- Neurocrine presents new data analyses from KINECT-HD study
- Neurocrine presents new data on patient-reported improvements with INGREZZA